Freja Bagatin

Dr. Freja Bagatin

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
FBFreja Bagatin
Freja Bagatin
APAnte Prpić
Ante Prpić
JHJelena Škunca Herman
Jelena Škunca Herman
OZOgnjen Zrinscak
Ognjen Zrinscak
RIRenata Ivekovic
Renata Ivekovic
ZVZoran Vatavuk
Zoran Vatavuk
This study explores the complication of secondary intraocular pressure (IOP) elevation and consequent glaucoma development in Graves’ orbitopathy (GO), an autoimmune disorder associated with hyperthyroidism. Utilizing Octopus 900 visual field testing and optical coherence tomography (OCT), the research established correlations between functional and structural changes in optic nerve regions in patients with GO and patients with GO with elevated IOP (GO IOP) groups. A comparison with primary open-angle glaucoma (POAG) was conducted in a cohort of 182 subjects. The study identifies optic nerve head parameters that effectively differentiate changes in GO and GO IOP groups. In the GO group, the strongest correlation between structural and functional changes was observed in sector 7, while in the GO IOP group, it was in sectors 1 and 7. For POAG, correlation was found in six sectors. Elevated IOP in GO correlates with structural and functional impairments similarly to early glaucoma. Risk factors for GO-related elevated IOP included older age, longer duration of thyroid disease, and higher anti-thyroglobulin values. The study highlights the significance of regular IOP measurements, visual field assessments, and OCT examinations in GO patients. Early antiglaucoma intervention is warranted when characteristic structural and functional changes and/or risk factors are identified.

1 December 2010
Verified
Journal Article
Closed access
ZMZdravko Mandić
Zdravko Mandić
KNKatia Novak-Laus
Katia Novak-Laus
LBLovro Bojić
Lovro Bojić
SPSmiljka Popović-Suić
Smiljka Popović-Suić
MEMiroslav Ekert
Miroslav Ekert
SKSuzana Kovacević
Suzana Kovacević

11 October 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
FBFreja Bagatin
Freja Bagatin
IRIvana Radman
Ivana Radman
KRKarla Randelovic
Karla Randelovic
IVIvanka Petric Vicković
Ivanka Petric Vicković
VLValentina Lacmanovic Loncar
Valentina Lacmanovic Loncar
ZVZoran Vatavuk
Zoran Vatavuk
Corneal crosslinking (CXL) is a medical procedure used to treat keratoconus. CXL works by strengthening the collagen fibers of the cornea through the application of riboflavin (vitamin B2) and ultraviolet (UV) light, which helps to stabilize the cornea and prevent further deterioration. There is a recognized risk that CXL can trigger the reactivation of dormant herpes simplex virus (HSV), leading to herpetic keratitis even in patients with no history of herpetic disease. We examined the medical history of 52 patients who underwent CXL procedures due to previously diagnosed keratoconus. We reviewed the patient’s medical histories to assess whether there was a herpes labialis infection and/or herpetic keratitis. Altogether, 52 eyes (from 52 patients) were analyzed. Of those, four (7.69%) patients were diagnosed with epithelial herpetic keratitis on the 5–8th day after surgery. All four patients had a history of herpes labialis and no prior HSV keratitis infection. Two patients developed herpetic keratitis despite prophylactic therapy with acyclovir 5 days before surgery. A positive history of HSV lip infection before CXL was present in 18/52 (34.62%). During a one-year follow-up period, no patient experienced a recurrence. Close follow-up is crucial for diagnosing herpetic keratitis after corneal crosslinking. The use of prophylactic antiviral therapy in patients who are asymptomatic and have a history of recurrent herpes labialis does not guarantee the prevention of infection.

1 June 2012
Verified
Journal Article
Closed access
FBFreja Bagatin
Freja Bagatin
ASAna Jurin Sicaja
Ana Jurin Sicaja
MRMaja Malenica Ravlić
Maja Malenica Ravlić
KNKatia Novak-Laus
Katia Novak-Laus
RIRenata Iveković
Renata Iveković
ZMZdravko Mandić
Zdravko Mandić

26 November 2025 in Medicina
Verified
Journal Article
Open access
PDF file
FBFreja Bagatin
Freja Bagatin
AVAnte Vukojević
Ante Vukojević
KRKarla Ranđelović
Karla Ranđelović
IRIvana Radman
Ivana Radman
RIRenata Ivekovic
Renata Ivekovic
ZVZoran Vatavuk
Zoran Vatavuk
Background and Objectives: Corneal cross-linking (CXL) is the standard treatment for progressive keratoconus, but delayed epithelial healing remains a concern, increasing infection risk and patient discomfort. Studies suggest that insulin may promote corneal epithelial cell migration and proliferation, potentially accelerating wound healing. Its benefit has been observed in neurotrophic keratitis and diabetic epithelial defects, and it may offer similar effects post-CXL. Our objective is to evaluate the effect of topical insulin on epithelial healing after CXL in a small case series. Materials and Methods: Eight patients undergoing CXL for keratoconus were divided into two groups (n = 4 each). The insulin group received topical insulin eye drops (1 IU/mL in Systane®) five times daily, in addition to standard postoperative care. The control group received Systane® alone with the same regimen. Daily follow-up included slit-lamp exam, anterior segment OCT, and photodocumentation until epithelial defect closure. Results: Baseline parameters (central corneal thickness, keratoconus stage, Schirmer test, tear break up test) were comparable. While not statistically significant, the insulin group showed numerically smaller epithelial defects on day 2, suggesting a possible trend toward faster healing. By day 3, re-epithelialization was complete in all patients. Pain decreased over time in both groups without significant differences. No adverse effects were noted. Conclusions: Topical insulin may modestly accelerate epithelial healing after CXL, as suggested by smaller defects on day 2 in the insulin group. Although results were not statistically significant, the trend warrants further investigation in larger studies.

17 July 2026 in Medicina
Verified
Journal Article
Open access
PDF file
FBFreja Bagatin
Freja Bagatin
RIRenata Ivekovic
Renata Ivekovic
IRIvana Barbić Radman
Ivana Barbić Radman
KRKarla Ranđelović
Karla Ranđelović
ZVZoran Vatavuk
Zoran Vatavuk
Background and Objectives: Achieving a postoperative refractive outcome close to the target is crucial in cataract surgery, as residual refractive errors can affect visual quality and patient satisfaction. Methods: This study evaluates the relationship between preoperative target refraction, postoperative intraocular lens (IOL) shift, and refractive stability. Prospective, observational study conducted at the Clinical Hospital Centre Sestre Milosrdnice, Zagreb, Croatia, involving patients undergoing routine cataract surgery with monofocal IOL implantation. Ninety-four eyes undergoing phacoemulsification with implantation of one of three monofocal IOLs (PCB00, RayOne HA, Akreos Adapt) were included. Preoperative biometry assessed axial length, anterior chamber depth, central corneal thickness, and white-to-white distance. Target refraction was −0.75 to 0.00 D. IOL position and refraction were measured at 1 week, 1 month, and 6 months postoperatively. Patient satisfaction was evaluated at all three time points. Results: All three IOLs demonstrated comparable in-the-bag stability over 6 months, with minimal longitudinal shift (all p > 0.05). Postoperative refractive outcomes were generally comparable, but RayOne HA showed a slightly more myopic deviation, whereas PCB00 and Akreos Adapt remained closer to emmetropia. The differences reflect the extent of deviation from the intended postoperative refraction, with statistically significant intergroup differences at 1 month (p = 0.004) and 6 months (p = 0.045). Conclusions: All three IOLs provided stable positioning and excellent visual outcomes. However, small differences in refractive predictability suggest that IOL design may influence the accuracy of target refraction. Tailoring target refraction according to IOL type may improve the likelihood of achieving emmetropia and optimize patient satisfaction.